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Colorectal carcinoma is the second most common malignancy in
the UK, with 31 230 men and women being diagnosed in 1995
(Cancer Research Campaign, 1998). At least 40% of these patients
ultimately develop metastatic disease (Mayer, 1992) and a further
20% develop locally advanced disease. Palliative cytotoxic
chemotherapy has been shown to prolong survival and improve
quality of life in several randomized studies (Nordic Gastro-
intestinal Tumour Adjuvant Therapy Group, 1992; Scheithauer et
al, 1993; Allen-Mersh et al, 1994) but new treatment regimens are
being sought to increase efficacy as the response rate is relatively
poor (Poon et al, 1989; Advanced Colorectal Cancer Meta-
Analysis Project, 1992).
With the development of more intensive treatment regimens, a
better understanding of the clinical parameters that can predict
response to chemotherapy is required. However, there is little
information on predicting which patients would benefit most from
treatment. In addition, by failing to stratify patients, some clinical
trials inappropriately promote or dismiss new treatment regimens.
The identification of factors predicting for response would enable
more accurate comparisons to be made between different thera-
peutic approaches.
To date, there has been little investigation into the parameters
that predict for response to chemotherapy, although it has been
recognized that poor performance status predicts for lack of
response to treatment (Steinberg et al, 1992). However, some
authors have studied those clinical parameters that might predict
for decreased survival, rather than response, such as poor differen-
tiation of primary tumour (Finan et al, 1985; Stangl et al, 1994;
Webb et al, 1995), low albumin (Finan et al, 1985; Steinberg et al,
1992; Fountzilas et al, 1996) and raised alkaline phosphatase
(Chang et al, 1989). Some studies have demonstrated that a raised
serum carcinoembryonic antigen (CEA) on presentation carries a
poor prognosis (Chang et al, 1989; Webb et al, 1995), while others
found there to be no significant correlation (Kouri et al, 1992,
1993).
So far, no studies have been performed specifically to evaluate
the importance of metastatic site as a prognostic indicator for
response to treatment and survival. There have been reports within
some studies that hepatic deposits are the most likely to respond
and peritoneal the least (Kouri et al, 1993; Hill et al, 1995a) but no
further evaluation of this potentially important prognostic indi-
cator has been performed. To determine whether metastatic site,
along with other clinical parameters, influences response rate and
survival in advanced colorectal carcinoma, we performed an
analysis of a cohort of 497 patients who had been entered into
prospective, randomized clinical trials (Hill et al, 1995a, 1995b;
Seymour et al, 1996; Ross et al, 1997).
METHODS
Patient eligibility
This study used a prospective database that had collected data in
the period from February 1990 to June 1996. The patients had
been in randomized clinical trials (Hill et al, 1995a, 1995b;
Seymour et al, 1996; Ross et al, 1997) with similar entry criteria
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Correspondence to: D Cunninghamand well-balanced pretreatment characteristics in the different
treatment arms. All patients had either inoperable locally-
advanced or metastatic histologically-proven colorectal adeno-
carcinoma. Some patients included in the group with peritoneal
disease also had omental disease. They were required to have
adequate bone marrow (platelets > 100 ´ 109 l–1 white cell count >
3 ´ 109 l–1), renal (creatinine < 132 mmol l–1, urea < 10.7 mmol l–1)
and hepatic (bilirubin < 30 mmol l–1) function, life expectancy of
at least 3 months and no previous malignancy or concurrent
uncontrolled medical illness. All were intention-to-treat trials and,
therefore, although performance status was 0–2 at the time of
randomization, the performance status could have deteriorated to 4
by the time of first course of treatment.
Pretreatment evaluation
Staging was performed by clinical assessment, full blood count
(FBC), renal and liver function tests, CEA and computed tomog-
raphy (CT) of the thorax, abdomen and pelvis. In addition, the
diagnostic histological sample was reviewed by a histopathologist
at the Royal Marsden Hospital. Performance status was assessed
according to World Health Organization (WHO) guidelines
(Miller et al, 1981).
Chemotherapy
In all patients this was the first palliative treatment. Those who 
had received prior adjuvant chemotherapy were eligible only if
this had been completed more than 12 months previously. 5-
Fluorouracil (5FU)-based chemotherapy was given to all patients
and the regimens used were:
(i) protracted venous infusion 5FU (300 mg m–2) with or
without interferon alpha (IFN) (n = 158) (Hill et al, 1995a)
(ii) protracted venous infusion 5FU (300 mg m–2) with or
without mitomycin C (n = 195) (Ross et al, 1997)
(iii) 5-day infusional 5FU (750 mg m–2 day–1) followed by
weekly bolus 5FU (750 mg m–2) with or without IFN 
(n = 110) (Hill et al, 1995b)
(iv) leucovorin (200 mg m–2) over 2 h then 5FU (400 mg m–2)
bolus and 5FU (400 mg m–2) by infusion over 22 h on day 2,
fortnightly with or without IFN (n = 34) (Seymour et al,
1996).
Evaluation of response
Tumour site, size and response was evaluated using CT scans at
10–12 weeks, and then after a further 10–12 weeks if there had
been a response. Tumour response was assessed according to the
WHO guidelines (Miller et al, 1981).
Statistical methods
Different potential prognostic subgroups of patients were defined
as a result of clinical experience and previous literature: age, sex,
performance status, site of primary tumour, differentiation of
primary tumour, Dukes staging at diagnosis, mode of administra-
tion of 5FU, site of metastasis, number of metastatic sites and
serum CEA, alkaline phosphatase and albumin on presentation. As
complete data on all clinical parameters were not available for
every patient, the sample size varied, with a minimum sample size
of 420 patients, unless individual sites of metastases were exam-
ined. When disease was not evaluable at a particular site, the
patient was excluded from that site analysis.
Univariate analyses were performed using the chi-squared (c2)
test to assess the parameters which had individual statistical signif-
icance on overall response rate and response for different sites.
Multivariate analysis was performed using step-wise logistic
regression to evaluate the potential prognostic factors and their
independent influence on overall response rate and response rate at
different metastatic sites. As performance status and the mode of
administration of 5-Fluorouracil are known to be strong predictors
for response, these factors were forced to remain in the multi-
variate analysis model for response at individual sites of metastatic
disease, effectively stratifying for these factors. Hazard ratios for
overall survival according to different variables was calculated
using Cox proportional hazards model. Results were considered
significant if the P value was less than 0.05.
RESULTS
The data for 497 patients who were treated within prospective
randomized studies between February 1990 and June 1996 was
analysed in December 1997. Patient characteristics are shown in
Table 1. There were 313 men and 184 women with a median age of
61 years (range 16–82 years). Sixty-six patients were alive at the last
follow-up with a median follow-up of 789.5 days (range 57–2305
days). Median survival was 333 days with 45.9% of patients alive at
1 year, 16.7% alive at 2 years and 9.2% alive at 3 years.
Table 2 demonstrates the most favourable response at each
metastatic site. 40% of patients with metastatic disease in the liver
had a complete response (CR) or partial response (PR) while a CR
or PR was achieved in 20.8% of lung metastases, 18.7% of nodal
disease and 15.3% of locoregional disease. Only 10.4% of patients
with peritoneal disease achieved a PR, with 68.7% having stable
disease (SD) and 20.9% having progressive disease (PD). Disease
was the most difficult to assess in patients with peritoneal
metastases (26.4%).
Univariate analysis
Univariate analysis was performed to assess the statistical signifi-
cance of various factors on response to treatment (Table 3). Eight
patients were not evaluable for overall response and were, there-
fore, excluded from the analysis. The significant positive prog-
nostic indicators for response were, in decreasing order, the
presence of one metastasis or locally advanced disease, albumin 
³ 35 g l–1, performance status of 0 or 1, administration of 5FU 
by protracted venous infusion (PVI) and alkaline phosphatase 
< 133 U l–1. Peritoneal (P = 0.006) and lung (P = 0.015) metastases
were significantly less likely than other sites of disease to respond
to chemotherapy. Age, sex, site of primary, differentiation of
primary, Dukes stage (not shown) and initial CEA did not predict
for response to chemotherapy.
Multivariate analysis
Overall response
A total of 420 patients were evaluable for overall response (Table
4). The presence of liver metastases was the most important factor
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for predicting response to chemotherapy (hazard ratio (HR) 2.27).
Also, having performance status of 0 or 1, one metastasis or
locally-advanced disease and administration of 5FU by PVI
predicted for response in decreasing order. On analysis, albumin 
³ 35 (HR 1.63) approached statistical significance as a positive
predictor for response. CEA ³ 5 (HR 0.62) and presence of peri-
toneal metastases (HR 0.56) indicated a significantly decreased
chance of a response to treatment.
Response rate according to site
The most significant predictor for response in liver metastases was
administration of 5FU by infusion (HR 3.01). Albumin ³ 35 on
presentation was as significant as performance status of 0 or 1 for
predicting response in liver metastases, while the presence of peri-
toneal metastases made response unlikely (HR 0.34) (Table 4).
There was no positive predictor for response in peritoneal
metastases on multivariate analysis. For response in lung
metastases, the synchronous presence of peritoneal metastases
approached statistical significance (P = 0.07) for a decreased
chance of response. Response was four times less likely in loco-
regional disease or distal nodes if CEA was raised on presentation.
Response in locoregional disease was more likely if there was only
one site of metastatic disease and if metastatic disease was present
in distal nodes.
Survival
Poor performance status, bolus administration of 5FU, CEA ³ 5,
albumin < 35, poor differentiation of initial tumour, presence of
peritoneal metastases, alkaline phosphatase ³ 133 and presence of
distal nodal metastases were associated with a significant increased
risk of mortality, in decreasing order (Table 5). The number of sites
of metastases on presentation had no influence on overall survival,
along with age, sex, site of primary and initial Dukes stage.
DISCUSSION
In order to accurately assess the efficacy of alternative treatment
regimens and compare different clinical trials, clarification of the
clinical parameters which can predict response to chemotherapy
and survival is required. The data for this review was collected
from one centre and, although it involved different clinical trials
and, therefore, different chemotherapy regimens, all regimens
involved 5FU and the trials required similar entry criteria. The
majority of the patients (n = 302) were involved in trials assessing
the effect of interferon, which has subsequently been shown to be
of no benefit (Hill et al, 1995a, 1995b; Kosmidis et al, 1996;
Recchia et al, 1996). Of the 497 patients, 99 received additional
mitomycin C which, in one study, conferred benefit on response
rate and failure-free survival, although no improvement in overall
survival (Ross et al, 1997). Response rate for the whole group was
similar to that previously reported (Kouri et al, 1992; Buroker et
al, 1994; Conti et al, 1995).
The most important positive predictor for overall response to
chemotherapy was the presence of liver metastases. Good perfor-
mance status, only one site of metastasis and delivery of 5FU by
PVI were also significant factors for response to chemotherapy. A
raised CEA and presence of peritoneal metastases significantly
decreased the chance of response.
By individual site, the opportunity for response was improved in
the liver with infusional 5FU, good performance status and normal
albumin. The synchronous presence of peritoneal metastases
significantly decreased the chance of response in the liver or lung.
A raised initial CEA was a negative predictive parameter for
locoregional and distant nodal disease and there were no reliable
predictive indicators for peritoneal metastases. Response to
chemotherapy, as assessed by CT, was achieved in 40% of patients
with liver metastases, 20.8% in lung metastases and only 10.4%
patients with peritoneal disease. It has recently been found that
there is a significantly higher level of thymidylate synthase (TS)
mRNA expression and TS protein in lung metastases compared
with liver metastases in colon carcinoma (Gorlick et al, 1998). As
high TS expression is known to be predictive of a poor response to
Table 1 Patient characteristics
Patient characteristics n
Sex
Male 313
Female 184 
Performance Status
01 1 3
1 244
2 111
32 1
41
Missing value 7
Site of Primary
Colon 324
Rectosigmoid/rectum 172
Missing value 1
Differentiation
Well 21
Moderate 388
Poor 64
Unknown 24
Dukes Stage
A9
B8 8
C 173
D 208
Unknown 19
CEA
< 5 89
³ 5 367
Missing value 41
Alkaline phosphatase
< 133 287
³ 133 208
Missing value 2
Albumin
< 35 144
³ 35 351
Missing value 2
5-Fluorouracil
PVI 353
Bolus 144
Number of metastatic sites
04 2
1 219
2 155
36 1
> 3 20
Metastatic site
Liver 361/497
Lung 134/497
Peritoneal 91/497
Locoregional 133/497
Distant nodes 118/497Metastatic site predicts for response in colorectal cancer 1803
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5FU (Johnston et al, 1995; Leichman et al, 1997; Yeh et al, 1998),
it may explain the lack of response observed in the lung metastases
compared with liver metastases in this cohort. It is probable that
further mechanisms of resistance to chemotherapy regimens will
be discovered in the future.
Poor performance status, treatment with bolus 5FU, raised
CEA, decreased albumin, poor differentiation of tumour and
raised alkaline phosphatase were all negative prognostic factors
for overall survival. In addition, overall survival was poorest for
those with peritoneal or distal nodal metastases, although the
presence of more than one site of metastasis on presentation was
not a significant predictor for survival.
A recent meta-analysis demonstrated that infusional 5FU was
superior to bolus 5FU for achieving a response in advanced
colorectal cancer and also conferred a slight increase in survival
(Meta-analysis Group In Cancer, 1998). Raised CEA (Kouri et al,
1993), poor performance status (Kouri et al, 1992, 1993; Kosmidis
et al, 1996) and poor differentiation of primary (Finan et al, 1985)
have been reported previously as significant poor indicators for
survival, as seen with our results. Contrary to our findings, age 
> 60 years (Kosmidis et al, 1996) and initial Dukes stage of
primary tumour (Finan et al, 1985) have been found previously to
be negative prognostic factors.
This study is unique for closely examining response and overall
survival according to site of metastatic disease. However, certain
weaknesses exist; slightly different 5FU-based chemotherapy regi-
mens were used and it only provides predictive information of
5FU-treated patients. Its relevance to newer chemotherapy agents,
such as irinotecan, which targets topoisomerase I instead of TS,
will need to be studied in future trials. No account of the degree of
replacement of the liver and lung by metastases was made and our
present imaging techniques, including CT scanning, are limited in
defining small foci of disease, such as in the peritoneum. In this
series, 91 patients had evidence of peritoneal metastases. Of these,
26.4% had non-evaluable disease, 69% had stable disease, 21%
had progressive disease and only 10% demonstrated a response to
treatment, thus reflecting the difficulty of assessing peritoneal
disease with CT scanning.
Nevertheless, metastatic involvement of the peritoneum, along
with poor performance status, raised CEA, decreased albumin and
treatment with bolus 5FU are important predictive indicators of
poor response rate and increased mortality for patients with
advanced colorectal cancer treated with 5FU. Response to
chemotherapy is more likely if there are metastases in the liver
and there is only one site of metastatic disease. Patients in
clinical trials should be stratified according to clinical parameters,
such as raised CEA, decreased albumin and site of metastasis on
presentation, in addition to performance status, so that accurate
comparisons between different treatment regimens can be made,
and to ensure that poor-risk patients are not inappropriately offered
potentially toxic chemotherapy.
Table 2 Response according to site of metastasis
Complete Partial Stable Progressive
response response disease disease Non-evaluable*
n (%) n (%) n (%) n (%) n (%)
Liver (n = 361) 13 (3.8) 124 (36.2) 169 (49.3) 37 (10.8) 18 (5.0)
Lung (n = 134) 3 (2.4) 23 (18.4) 85 (68.0) 14 (11.2) 9 (6.7)
Locoregional (n = 133) 1 (0.9) 16 (14.4) 83 (74.8) 11 (9.9) 22 (16.5)
Nodal (n = 118) 4 (3.7) 16 (15.0) 86 (80.4) 1 (0.9) 11 (9.3)
Peritoneal (n = 91) – 7 (10.4) 46 (68.7) 14 (20.9) 24 (26.4)
*Non-evaluable patients not included in the denominator for response by site
Table 3 Univariate analysis of prognostic factors for overall response
Number  evaluable Response rate (%) P
Age
<61 245 34.3
³61 244 34.4 0.974
Sex
Male 309 35.3 0.575
Female 180 32.8
Performance status
0–1 351 39.3 0.0002
2–4 131 21.4
Site of primary
Colon 320 35.3 0.540
Rectum 169 32.5
Differentiation
Well/Mod 401 34.7
Poor 64 35.9 0.843
CEA
< 5 85 42.4 0.085
³ 5 363 32.5
Alkaline phosphatase
< 133 280 38.2 0.034
³ 133 207 29.0
Albumin
< 35 144 20.1
³ 35 343 40.2 < 0.0001
5-Fluorouracil
PVI 345 38.6 0.003
Bolus 144 24.3
Number of metastatic sites
0–1 255 42.4 < 0.0001
³ 2 234 25.6
Liver metastases
No 133 28.6
Yes 356 36.5 0.100
Lung metastases
No 357 37.5 0.015
Yes 132 25.8
Peritoneal metastases
No 398 37.2 0.006
Yes 91 22.0
Nodal metastases
No 368 36.7 0.059
Yes 121 27.31804 L Assersohn et al
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